ALKS insider transaction filings
Alkermes plc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-17. Screen ALKS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-17 | 4 | Nichols Christian Todd — SVP, Chief Commercial Officer | Sale (S): 6,912 @ $49.19 · Sale (S): 664 @ $49.65 | EDGAR |
| 2026-08-07 | 4 | Jackson Blair Curtis — President & CEO, Alkermes plc, Director | Grant/award (A): 93,229 (derivative) @ $0 · Grant/award (A): 124,305 (derivative) @ $0 | EDGAR |
| 2026-08-03 | 4 | snyderman nancy lynn MD — Director | Option exercise (M): 27,948 @ $46.72 · Option exercise (M): 16,524 @ $46.72 · Sale (S): 44,472 @ $50.35 · Option exercise (M): 27,948 (derivative) @ $0 · Option exercise (M): 16,524 (derivative) @ $0 | EDGAR |
| 2026-08-03 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 104 @ $19.34 · Option exercise (M): 4,896 @ $24.59 · Sale (S): 9,000 @ $48.58 · Option exercise (M): 104 (derivative) @ $0 · Option exercise (M): 4,896 (derivative) @ $0 | EDGAR |
| 2026-08-03 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Sale (S): 2,034 @ $48.58 | EDGAR |
| 2026-07-06 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Sale (S): 2,034 @ $54.03 | EDGAR |
| 2026-07-01 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 5,000 @ $19.34 · Sale (S): 8,300 @ $51.46 · Sale (S): 700 @ $52.13 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Wright Christopher I — Director | Sale (S): 2,000 @ $45.10 | EDGAR |
| 2026-06-04 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Sale (S): 2,034 @ $43.05 | EDGAR |
| 2026-06-01 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 5,000 @ $19.34 · Sale (S): 9,000 @ $41.67 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Parisi Samuel Joseph — VP, Finance (Interim PAO) | Option exercise (M): 3,392 @ $20.03 · Option exercise (M): 12,825 @ $19.34 · Sale (S): 16,217 @ $42.36 · Option exercise (M): 3,392 (derivative) @ $0 · Option exercise (M): 12,825 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Wright Christopher I — Director | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-22 | 4 | snyderman nancy lynn MD — Director | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-22 | 4 | GAYNOR RICHARD — Director | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-22 | 4 | Cooke Shane — Director | Option exercise (M): 6,142 · Tax withholding (F): 3,207 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-22 | 4/A | GAYNOR RICHARD — Director | Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4/A | Cooke Shane — Director | Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Wilson Frank Anders — Director | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-22 | 4 | Lurker Nancy — Director | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-22 | 4 | LAURENCIN CATO T — Director | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-22 | 4 | MCKEON BRIAN P — Director | Option exercise (M): 6,142 · Tax withholding (F): 1,475 @ $36.95 · Grant/award (A): 11,538 (derivative) @ $0 · Grant/award (A): 5,409 (derivative) @ $0 · Option exercise (M): 6,142 (derivative) | EDGAR |
| 2026-05-04 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Sale (S): 2,034 @ $33.20 | EDGAR |
| 2026-05-01 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 5,000 @ $19.34 · Sale (S): 9,000 @ $33.40 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | Lurker Nancy — Director | Option exercise (M): 3,751 · Tax withholding (F): 901 @ $33.36 · Option exercise (M): 3,751 (derivative) | EDGAR |
| 2026-04-06 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Sale (S): 2,034 @ $34.57 | EDGAR |
| 2026-04-01 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 5,000 @ $19.34 · Sale (S): 9,000 @ $35.51 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Reed Joshua — SVP, Chief Financial Officer | Grant/award (A): 66,430 (derivative) @ $0 · Grant/award (A): 30,854 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Parisi Samuel Joseph — VP, Finance (Interim PAO) | Sale (S): 6,890 @ $29.29 · Grant/award (A): 15,033 (derivative) @ $0 · Grant/award (A): 14,176 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Nichols Christian Todd — SVP, Chief Commercial Officer | Sale (S): 6,000 @ $30 · Grant/award (A): 66,430 (derivative) @ $0 · Grant/award (A): 30,854 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Jackson Blair Curtis — EVP, Chief Operating Officer | Grant/award (A): 94,900 (derivative) @ $0 · Grant/award (A): 44,078 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 5,000 @ $19.34 · Sale (S): 9,000 @ $29.72 · Option exercise (M): 5,000 (derivative) @ $0 · Grant/award (A): 83,037 (derivative) @ $0 · Grant/award (A): 38,568 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Sale (S): 2,034 @ $29.29 · Sale (S): 2,034 @ $29.76 · Grant/award (A): 78,292 (derivative) @ $0 · Grant/award (A): 36,364 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | POPS RICHARD F — Director and CEO, Alkermes plc, Director | Grant/award (A): 88,843 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Parisi Samuel Joseph — VP, Finance (Interim PAO) | Option exercise (M): 2,747 · Tax withholding (F): 808 @ $30.73 · Option exercise (M): 2,747 (derivative) | EDGAR |
| 2026-02-27 | 4 | Nichols Christian Todd — SVP, Chief Commercial Officer | Option exercise (M): 5,410 · Tax withholding (F): 2,403 @ $30.73 · Option exercise (M): 5,410 (derivative) | EDGAR |
| 2026-02-27 | 4 | Jackson Blair Curtis — EVP, Chief Operating Officer | Option exercise (M): 8,322 · Tax withholding (F): 3,695 @ $30.73 · Option exercise (M): 8,322 (derivative) | EDGAR |
| 2026-02-27 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 6,866 · Tax withholding (F): 3,049 @ $30.73 · Option exercise (M): 6,866 (derivative) | EDGAR |
| 2026-02-27 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Option exercise (M): 6,866 · Tax withholding (F): 3,049 @ $30.73 · Option exercise (M): 6,866 (derivative) | EDGAR |
| 2026-02-25 | 4 | Parisi Samuel Joseph — VP, Finance (Interim PAO) | Option exercise (M): 2,283 · Tax withholding (F): 672 @ $32.19 · Option exercise (M): 2,283 (derivative) | EDGAR |
| 2026-02-25 | 4 | Nichols Christian Todd — SVP, Chief Commercial Officer | Option exercise (M): 6,407 · Tax withholding (F): 2,845 @ $32.19 · Option exercise (M): 6,407 (derivative) | EDGAR |
| 2026-02-25 | 4 | Jackson Blair Curtis — EVP, Chief Operating Officer | Option exercise (M): 8,738 · Tax withholding (F): 3,880 @ $32.19 · Option exercise (M): 8,738 (derivative) | EDGAR |
| 2026-02-25 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 7,689 · Tax withholding (F): 3,414 @ $32.19 · Option exercise (M): 7,689 (derivative) | EDGAR |
| 2026-02-25 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Option exercise (M): 7,689 · Tax withholding (F): 3,414 @ $32.19 · Option exercise (M): 7,689 (derivative) | EDGAR |
| 2026-02-20 | 4 | Parisi Samuel Joseph — VP, Finance (Interim PAO) | Option exercise (M): 2,034 · Tax withholding (F): 706 @ $32.02 · Option exercise (M): 2,991 · Tax withholding (F): 979 @ $32 · Option exercise (M): 2,034 (derivative) · Option exercise (M): 2,991 (derivative) | EDGAR |
| 2026-02-20 | 4 | Nichols Christian Todd — SVP, Chief Commercial Officer | Option exercise (M): 6,355 · Tax withholding (F): 1,869 @ $32.02 · Option exercise (M): 6,045 · Tax withholding (F): 2,277 @ $32 · Option exercise (M): 6,355 (derivative) · Option exercise (M): 6,045 (derivative) | EDGAR |
| 2026-02-20 | 4 | Jackson Blair Curtis — EVP, Chief Operating Officer | Option exercise (M): 8,897 · Tax withholding (F): 3,796 @ $32.02 · Option exercise (M): 9,300 · Tax withholding (F): 4,130 @ $32 · Option exercise (M): 8,897 (derivative) · Option exercise (M): 9,300 (derivative) | EDGAR |
| 2026-02-20 | 4 | Hopkinson Craig C. — EVP R&D, Chief Medical Officer | Option exercise (M): 8,897 · Tax withholding (F): 3,504 @ $32.02 · Option exercise (M): 7,673 · Tax withholding (F): 3,407 @ $32 · Option exercise (M): 8,897 (derivative) · Option exercise (M): 7,673 (derivative) | EDGAR |
| 2026-02-20 | 4 | Gaffin David Joseph — EVP, CLO, Alkermes, Inc. | Option exercise (M): 6,355 · Tax withholding (F): 2,126 @ $32.02 · Option exercise (M): 7,673 · Tax withholding (F): 3,407 @ $32 · Option exercise (M): 6,355 (derivative) · Option exercise (M): 7,673 (derivative) | EDGAR |
| 2026-02-06 | 4 | Nichols Christian Todd — SVP, Chief Commercial Officer | Grant/award (A): 21,127 · Tax withholding (F): 6,389 @ $33.55 | EDGAR |
| 2026-02-06 | 4 | Jackson Blair Curtis — EVP, Chief Operating Officer | Grant/award (A): 28,810 · Tax withholding (F): 8,626 @ $33.55 | EDGAR |
Recent 8-K events — Alkermes plc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-08 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-06-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ALKS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →